PARABILIS MEDICINES’ ZOLUCATETIDE, THE FIRST AND ONLY DIRECT INHIBITOR OF THE ELUSIVE Β-CATENIN:TCF INTERACTION, RECEIVES FDA ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF DESMOID TUMORS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.